Modelling in economic evaluation is an unavoidable fact of life. Cohort-based state transition models are most common, though discrete event simulation (DES) is increasingly being …
National liver transplantation (LT) volume has declined since 2006, in part because of worsening donor organ quality. Trends that degrade organ quality are expected to continue …
Background There is an urgent need to update diabetes prediction, which has relied on the United Kingdom Prospective Diabetes Study (UKPDS) that dates back to 1970 s' European …
P McEwan, AR Morgan, R Boyce… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE …
J Zhu, Y Zhou, Q Li, G Wang - Advances in Therapy, 2023 - Springer
Introduction Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …
BD Bradley, T Jung, A Tandon-Verma, B Khoury… - Health research policy …, 2017 - Springer
Background Operations research (OR) is a discipline that uses advanced analytical methods (eg simulation, optimisation, decision analysis) to better understand complex systems and …
J Geng, H Yu, Y Mao, P Zhang, Y Chen - Pharmacoeconomics, 2015 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have …
T Tandon, AK Dubey, S Srivastava… - Journal of Family …, 2019 - journals.lww.com
Background: With the available evidence of early combined oral drug therapies being more effective in lowering blood glucose levels than maximal doses of a single drug, many …
M Pesonen, V Jylhä, E Kankaanpää - JBI Evidence Synthesis, 2024 - journals.lww.com
Objective: The objective of this review was to examine the role of adverse drug events (ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …